Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25075441 | 0.93 | PRMT6 (0.33) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL26742235 | 0.88 | GNAO1 (0.38) | GNAO1GNAI3GNAI1SIGMAR1HRH3 | |
| SCHEMBL26497267 | 0.87 | GNAO1 (0.38) | GNAO1GNAI3GNAI1KCNH2SIGMAR1 | |
| SCHEMBL26494066 | 0.87 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL10092695 | 0.85 | GNAO1 (0.46) | GNAO1GNAI3GNAI1KCNH2HRH3 | |
| SCHEMBL25075203 | 0.85 | GNAO1 (0.39) | GNAO1GNAI3GNAI1KCNH2SLC6A2 | |
| SCHEMBL26494080 | 0.83 | NPC1 (0.45) | GNAO1GNAI3GNAI1 | |
| SCHEMBL25108944 | 0.81 | SIGMAR1 (0.42) | GNAO1GNAI3GNAI1KCNH2SIGMAR1 | |
| SCHEMBL10092707 | 0.81 | DRD2 (0.42) | GNAO1GNAI3GNAI1KCNH2SLC6A4 | |
| SCHEMBL17515335 | 0.81 | CYP1A2 (0.44) | KCNH2SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | GNAO1 3018/4885GNAI3 1728/4885GNAI1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.